Objective-Lysophosphatidic acid (LPA) is a bioactive lipid molecule produced by the plasma lysophospholipase D enzyme autotaxin that is present at Ն100 nmol/L in plasma. Local administration of LPA promotes systemic arterial remodeling in rodents. To determine whether LPA contributes to remodeling of the pulmonary vasculature, we examined responses in mice with alterations in LPA signaling and metabolism. Methods and Results-Enpp2 ϩ/Ϫ mice, which are heterozygous for the autotaxin-encoding gene and which have reduced expression of autotaxin/lysophospholipase D and approximately half normal plasma LPA, were hyperresponsive to hypoxia-induced vasoconstriction and remodeling, as evidenced by the development of higher right ventricular (RV) systolic pressure, greater decline in peak flow velocity across the pulmonary valve, and a higher percentage of muscularized arterioles. Mice lacking LPA 1 and LPA 2 , 2 LPA receptors abundantly expressed in the vasculature, also had enhanced hypoxia-induced pulmonary remodeling. With age, Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice spontaneously developed elevated RV systolic pressure and RV hypertrophy that was not observed in Lpar1 Ϫ/Ϫ mice or Lpar2 Ϫ/Ϫ mice. Expression of endothelin-1, a potent vasoconstrictor, was elevated in lungs of Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice, and expression of endothelin B receptor, which promotes vasodilation and clears endothelin, was reduced in Enpp2 ϩ/Ϫ and Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice. Conclusion-Our findings indicate that LPA may negatively regulate pulmonary vascular pressure through LPA 1 and LPA 2 receptors and that in the absence of LPA signaling, upregulation in the endothelin system favors remodeling. (Arterioscler Thromb Vasc Biol. 2012;32:24-32.)
A rterial smooth muscle cells (SMCs) regulate vessel contraction and relaxation and, following systemic vascular injury, can undergo phenotypic modulation to a proliferative/synthetic state that likely contributes to the development of atherosclerosis and restenosis. 1 In the highly compliant pulmonary circulation, large changes in blood flow are accommodated with little alteration of pressure by tightly coordinated vasoactive mediators. Dysregulation in the balance between pulmonary vasodilators and vasoconstrictors can trigger pulmonary vascular remodeling, characterized by an increase in pulmonary SMC proliferation, hypertrophy, and the number of SMC-wrapped small arterioles. As a consequence, pulmonary hypertension (PH) with elevated pulmonary vascular resistance and sustained high pulmonary arterial pressure develops. [2] [3] [4] Endothelial dysfunction, including an increase in endothelial permeability and apoptosis, is associated with and likely promotes PH. 2, 4, 5 With time, the increase in pulmonary vascular resistance and pressure results in right ventricular (RV) hypertrophy, dilatation, and dysfunction. 4, 6 Cardiopulmonary disorders associated with ele-vated pulmonary artery pressures are one of the leading causes of RV hypertrophy and failure. 7 Unfortunately, at present, very little is known about the mediators that initiate pulmonary vascular changes underlying PH, making prevention and effective treatment of the disease challenging. 8 Lysophosphatidic acid (LPA) is a bioactive lipid molecule present in plasma concentrations (Ն100 nmol/L) predicted to activate its signaling receptors. 9, 10 LPA has effects on cultured SMCs and endothelial cells that make it an attractive candidate regulator of the pulmonary vasculature in vivo. 11 LPA is a potent autocrine regulator of phenotypic modulation of cultured vascular SMCs. Indeed, LPA has been proposed to be the major mediator in serum responsible for dedifferentiation of cultured vascular SMCs. Moreover, local administration of LPA in carotid arteries of rodents triggers a remodeling response, which requires SMC dedifferentiation and proliferation. [12] [13] [14] [15] [16] [17] LPA may also have important effects on endothelial cell function and endothelial barrier stability. 18 -20 In isolated cell systems, LPA has been reported to affect endothelial nitric oxide synthase activity and, conse-quently, nitric oxide levels, as well as endothelin levels, both important regulators of pulmonary vascular tone. [21] [22] [23] Thus, LPA has actions on both vascular SMCs and endothelial cells that trigger a dysregulation in their function that is similar to what is observed in a variety of pathological conditions, including PH. However, until recently, tools to probe the role of the autotaxin-LPA signaling nexus in vascular pathophysiology were not available.
Recent progress in identifying enzymes and receptors responsible for LPA metabolism and signaling has enabled the development of mouse models and pharmacological tools to investigate the involvement of LPA in cardiovascular regulation and function. LPA signaling responses are mediated by selective G protein-coupled receptors. Eight G protein-coupled receptors for LPA (LPA 1-8 ) have been identified. 18, 20, 21, 22 LPA 1 and LPA 2 are abundantly expressed in vascular SMCs and endothelial cells. 23, 24 In vitro studies in cell lines reveal that LPA receptors share certain function redundancy. 18, 19, 25 Although a complete range of subtype specific receptor antagonists is not presently available, the use of LPA receptor-selective probes and studies of mice with genetic deletion of LPA receptors have provided valuable information on their pathophysiologic roles in diverse settings, including neuropathic pain, lung inflammation, reproduction, and vascular injury responses. 26 LPA is produced in the blood and other tissues through hydrolysis of lysophosphatidylcholine, catalyzed by the secreted enzyme autotaxin/ lysophospholipase D encoded by the ectonucleotide pyrophosphatase/phosphodiesterase 2 (ENPP2) gene. 10 Enpp2 Ϫ/Ϫ mice die embryonically and display defects on vessel maturation. Enpp2 ϩ/Ϫ mice are viable but have approximately half the normal circulating autotaxin/lysophospholipase D and LPA levels. 27 Substantial evidence identifies a role for LPA in regulating phenotypic modulation of cultured vascular SMCs that can be recapitulated in vivo by local administration of LPA to systemic arteries. 12, 17 The use of mice with genetic deficiencies and small molecule inhibitors of LPA receptors supports a role for the autotaxin-LPA signaling nexus in systemic arterial remodeling in rodent models. In this study, we used mice with alterations in LPA signaling and metabolism and previously characterized models of PH 28 to identify an unexpected role for LPA in regulation of the pulmonary vasculature and hypoxia-induced remodeling.
Methods
All procedures conformed to the recommendations of the Guide for the Care and Use of Laboratory Animals (Department of Health, Education, and Welfare publication number NIH 78 -23, 1996, University of Kentucky) and were approved by the institutional animal care and use committee. Generation and characterization of Enpp2 ϩ/Ϫ and Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice were as previously described. 27,29 -31 The Enpp2 ϩ/Ϫ mice were backcrossed Ͼ10 generations to the FVB background, whereas the Lpar1 Ϫ/Ϫ , Lpar2 Ϫ/Ϫ , and Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice were backcrossed Ͼ10 generations to the BALB/c background. Mice were housed in cages with HEPA-filtered air in rooms on 14-hour light cycles and fed Purina 5058 rodent chow ad libitum. Details of the methods are included in the supplemental materials, available online at http://atvb.ahajournals.org.
Statistics
All results were expressed as meanϮSD. In vitro studies were repeated a minimum of 3 times, and results were analyzed by the Student t test or ANOVA. Statistical significance within strains was determined using ANOVA with multiple pair-wise comparisons. Statistical analysis was performed using Sigma-STAT software, version 3.5 (Systat Software Inc). Changes with a probability value of less than 0.05 for a type I error were considered significant. 32
Results

Reduction in Autotaxin/Lysophospholipase D Levels Promotes Hypoxia-Induced Pulmonary Remodeling in Mice
LPA promotes phenotypic modulation of cultured vascular SMCs and systemic arterial remodeling in experimental models. 12, 17 To determine whether LPA contributes to remodeling of the pulmonary vasculature, we examined responses in mice engineered to have reduction in LPA synthesis. Heterozygous Enpp2 ϩ/Ϫ mice have 50% of normal plasma LPA levels but no obvious vascular developmental abnormalities. 27 We previously reported lower autotaxin protein levels in the lungs of Enpp2 ϩ/Ϫ mice. 29 In keeping with those observations, Enpp2 mRNA expression in lungs of Enpp2 ϩ/Ϫ mice was 20Ϯ10% that in lungs from wild-type (WT) littermate controls (PϽ0.05). No difference in lung expression of LPA1-5 receptor mRNA was observed in Enpp2 ϩ/Ϫ mice (data not shown).
We used a hypoxia model to stimulate pulmonary vasoconstriction and promote vascular remodeling. 28 Exposure of WT mice to hypoxia (FiO 2 ϭ0.1) increases pulmonary arterial pressure, which can be monitored by measuring right ventricular systolic pressure (RVSP) ( Figure 1A ). Following exposure to hypoxia for 3 weeks, a significant increase in RVSP occurred in WT mice (30.3Ϯ2.3 mm Hg; nϭ6) compared with RVSP in age-matched normoxic littermates (25.7Ϯ2.1 mm Hg; nϭ6; PϽ0.05). Under normoxic conditions, Enpp2 ϩ/Ϫ mice displayed an RVSP (23.8Ϯ1.8 mm Hg; nϭ5) similar to that of their WT littermates ( Figure 1A ). However, following a 3-week exposure to hypoxia, Enpp2 ϩ/Ϫ mice developed higher RVSP (36.2Ϯ5.2 mm Hg; nϭ7; PϽ0.05) than WT littermate mice ( Figure 1A ). Peak flow velocity across the pulmonary valve decreased by 8.0Ϯ5.7% following hypoxia in WT mice. The decline in peak flow velocity was approximately twice as great (16.2Ϯ8.4%) in Enpp2 ϩ/Ϫ littermates after exposure to hypoxia (Table 1) .
To evaluate the role of pulmonary vascular remodeling in the enhanced RVSP and peak flow response of the Enpp2 ϩ/Ϫ mice to hypoxia, we examined muscularization of small pulmonary arterioles. Lung sections stained with ␣-smooth muscle actin, a marker for SMCs, were scored for non-, partially, and fully muscularized small pulmonary arterioles. The overall pulmonary histology of Enpp2 ϩ/Ϫ mice was not notably different from WT controls; in particular, WT and Enpp2 ϩ/Ϫ littermates maintained in normoxic conditions did not differ in the percentage of muscularized arterioles. Following a 3-week exposure to hypoxia, the percentage of muscularized small arterioles increased by Ϸ1.75-fold in WT mice. Lungs from Enpp2 ϩ/Ϫ mice exposed to hypoxia had a higher percentage of fully muscularized and a lower percentage of nonmuscularized distal small arterioles than did those of WT controls ( Figure 1B ). Thus, by 3 parameters, Enpp2 ϩ/Ϫ mice showed an exaggerated pulmonary vascular response to hypoxia consistent with an augmentation in hypoxia-induced PH.
Genetic Inactivation of LPA 1 and LPA 2 Promotes Hypoxia-Induced Pulmonary Remodeling in Mice
The exaggerated response of the pulmonary vasculature of Enpp2 ϩ/Ϫ mice to hypoxia suggests that LPA signaling may be protective in this setting. We therefore predicted that inactivation of the relevant LPA receptors would also result in exaggerated remodeling responses to hypoxia. LPA 1 and LPA 2 receptors are reported to be abundantly expressed in cultured endothelial and vascular SMCs. 23, 24 We observed relatively high expression in murine blood vessels, making these receptors candidates for mediating the pulmonary vascular remodeling responses. WT and Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice (8 -14 weeks old) were subjected to hypoxia for 3 weeks.
Exposure of Enpp2 ϩ/Ϫ , which are on the FVB background, to hypoxia did not result in mortality. However, the Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice are on the BALB/c background, and Ϸ10% of the WT mice and Ϸ55% of the Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice died during the 3-week exposure to hypoxia. The surviving Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice displayed evidence of hemodynamic compromise (heart rate Ͻ300 bpm), and therefore, we were unable to obtain accurate RVSP measurements following exposure to hypoxia. Because sustained elevation in RVSP produces RV hypertrophy, we analyzed heart cross-sections to detect RV hypertrophy as an indirect marker for RVSP. In comparison with WT mice, Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice developed more pronounced RV hypertrophy after hypoxia (Figure 2A and 2B). Similar to Enpp2 ϩ/Ϫ mice, the Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice had an approximately 2-fold greater reduction in peak flow velocity across the pulmonary valve after hypoxia than their WT controls ( Table 2 ). Analysis of the lungs revealed significantly more muscularized and fewer nonmuscularized pulmonary arterioles in Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice than in agematched WT controls ( Figure 2C ). Likewise, Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice had thicker pulmonary arteriolar walls, suggesting positive arteriolar remodeling ( Figure 2D ). Together, these results indicate that mice lacking LPA signaling through LPA 1 and LPA 2 receptors were hyperresponsive to hypoxiainduced pulmonary remodeling and RV hypertrophy, providing further support for a protective role of LPA signaling in the pulmonary vasculature and indicating that these effects are mediated by LPA 1 and LPA 2 . Results are presented as meanϮSD in mm/s.
Mice Lacking LPA 1 and LPA 2 Develop PH With Age
Under normoxic conditions, the pulmonary arterioles in Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice were more muscularized and thicker than those in WT control mice ( Figure 2C and 2D). Changes in elastin content often accompany vascular remodeling. Elastin gene expression (Eln) in lungs from Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice was 1.9Ϯ0.37-fold higher than in WT controls, and quantification of elastin staining on lung sections confirmed an increase in perivascular elastin content in Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice ( Figure  3A-3C ). Together, these observations indicate that alterations in the pulmonary vasculature occur in Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice even in the absence of hypoxia. To determine whether these alterations promoted the subsequent development of pulmonary arterial hypertension, we measured RVSP in young and old Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice. Although no significant difference in RVSP was observed in WT and Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice at age 8 to 14 weeks ( Figure 4A ), Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice developed an age-dependent increase in RVSP (58.5Ϯ4.5 versus 28.6Ϯ8.0 mm Hg in WT mice; PϽ0.05) that did not occur in age-matched Lpar1 Ϫ/Ϫ or Lpar2 Ϫ/Ϫ mice ( Figure 4B ). In agreement with the age-dependent elevation in RVSP observed in Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice, peak flow velocity across the pulmonary valve was 11% lower in Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ (nϭ18) than in WT (nϭ22; PϽ0.05) mice at 2 to 3 months of age and declined further in Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice with age, such that by 6 to 9 months of age, the peak flow velocity was 18% lower in the Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice (nϭ14) than in WT controls (nϭ11; PϽ0.001) ( Table 3 ). In keeping with the elevated RVSP, histological sections of hearts revealed thicker RV free walls and enlarged RV chambers in older Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice ( Figure 4C) , which was not observed in Lpar1 Ϫ/Ϫ or Lpar2 Ϫ/Ϫ mice ( Figure 4D) . No difference in the number of cardiomyocyte nuclei in the RV was observed in heart cross-sections. The average cross-section area of individual cardiomyocytes in the Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ RV tended to be larger than in WT mice, but the difference did not reach statistical significance (Pϭ0.057) (Supplemental Figure I) . We previously reported that systemic blood pressure was normal in Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice. 1 No difference in LV cardiomyocyte size, LV wall thickness, or LV ejection fraction was observed in Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice, suggesting that the alterations were RV specific (Supplemental Figure I and We excluded hypoxia as a cause for pulmonary arterial hypertension in Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice. Arterial oxygen saturation in WT mice was 96Ϯ1% and 97Ϯ1% at 1 to 2 months and 6 months of age, respectively. Corresponding values in the Lpa1 Ϫ/Ϫ 2 Ϫ/Ϫ mice were 95Ϯ2%, 97Ϯ0.3%, and 96Ϯ2% at 1 to 2 months, 3 to 4 months, and Ͼ6 months of age, respectively. Additionally, hemoglobin (17.6Ϯ1.3 g/dL) and hematocrit (53.3Ϯ4.4%) values in Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice did not differ from age-matched WT (17.4Ϯ1.6 g/dL and 55.3Ϯ7.9%), indicating that the Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice did not develop secondary polycythemia, which would be expected to occur in the setting of prolonged hypoxia (Supplemental Figure II) . Because alterations in endothelial permeability have been reported to contribute to the development of PH, we examined pulmonary vascular permeability in Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice. Following intravascular administration, Evans Blue dye accumulation in the lung tissue of WT and Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice was similar after normalization to wet lung weight (Supplemental Figure IIIA) . In accordance with Evans Blue data, no histological evidence of edema was seen in the lung tissue of Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice, and wet lung weight/leg bone length was the same in Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ and WT mice. Examination of pulmonary valves did not reveal any notable abnormalities of Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice, excluding pulmonary stenosis as a cause for the elevated RVSP (Supplemental Figure IIIB) . Plastic casting and microcomputed tomography analysis of the pulmonary vasculature also did not reveal obvious obstruction in the structure of the main pulmonary artery (data not shown). Results are presented as meanϮSD in mm/s. In light of the established role of LPA as a stimulus for arterial vascular remodeling and in provoking acute increases in systemic blood pressure in WT and Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice, 1, 17 the heightened pulmonary vascular remodeling in mice with attenuated LPA signaling suggested that perhaps LPA has different effects in the systemic and pulmonary vasculature. Therefore, we investigated acute LPA responses in isolated pulmonary-cell and organ models. Analogous to observations in aortic SMCs, 1 LPA stimulated migration of cultured human pulmonary arterial SMCs by 11.6-fold and reduced by 34% expression of SMC-specific myosin heavy chain, a SMC differentiation marker. Infusion of LPA (up to 10 mol/L) into an isolated buffer-perfused and ventilated mouse lung system did not alter pulmonary artery pressure, under conditions where thrombin (1 U/mL) increased pulmonary artery pressure on average by 130% (from a mean of 5.4Ϯ1.2 to 7.1Ϯ2 mm Hg). Together, these results suggest that the phenotype observed in the Enpp2 ϩ/Ϫ and Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice may be due to an indirect effect of loss of LPA signaling on another mediator(s).
Table 2. Peak Flow Velocity Across the Pulmonary Valve Before and After 3 wk of Exposure to Hypoxia
Alterations in Endothelin Signaling in Enpp2
To understand the basis for the enhanced response in the pulmonary vasculature of mice with attenuated LPA production, we examined expression of mediators implicated in regulating pulmonary vasoconstriction and vasodilation in the Enpp2 ϩ/Ϫ mice. Vegfr2, Pde5a, and Nos3 expression were normal in Enpp2 ϩ/Ϫ lungs. Exposure to hypoxia produced a 30% to 40% increase in Vegfr2 and Pde5a expression and a decline of 50% in Nos3 expression in WT mice. Similar changes occurred in Enpp2 ϩ/Ϫ mice. Exposure to hypoxia increased expression of Edn1 (encoding for endothelin-1, the most potent vasoconstrictor in the pulmonary circulation) in WT and Enpp2 ϩ/Ϫ by 50%. Hypoxia had no effect on expression of Ednra (endothelin [ET] A receptor) but reduced lung expression of Ednrb (ET B receptor) by 61Ϯ11% in WT mice (PϽ0.05). Interestingly, Ednrb expression was 30Ϯ1% lower in Enpp2 ϩ/Ϫ than WT mice at baseline (PϽ0.05) and declined further with hypoxia (PϽ0.05). On the other hand, the expression levels of Edn1 and Ednra were similar in WT and Enpp2 ϩ/Ϫ mice at baseline or with hypoxia (Supplemental Figure IV) . ET B is a vasodilatory and clearing receptor for endothelin. Reduced levels of ET B have been associated with acceleration of PH. 33 Thus, an alteration in ET B expression is a possible explanation for the enhanced remodeling response of Enpp2 ϩ/Ϫ mice. Hypoxia treatment did not have significant effect on the expression levels of Lpar1 to Lpar5 in Enpp2 ϩ/Ϫ mice (data not shown).
Next, we examined expression profiles of mediators known to influence development and hypoxia responses in LPA 1 and LPA 2 deficient mice. In keeping with the observations in Enpp2 ϩ/Ϫ mice, no differences in Vegfr2, Pde5a, and Nos3 expression were observed between WT and Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice exposed to normoxic conditions, and both responded with a similar increase in Vegfr2 and Pde5a expression and decline in Nos3 expression following hypoxia (data not shown). However, the expression levels of Edn1, which encodes endothelin-1 (ET-1), and Ednra, which encodes the vasoconstrictive ET A receptor, were significantly higher in Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice than in WT controls ( Figure 5A ). As in the Enpp2 ϩ/Ϫ mice, Ednrb expression was lower in Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice ( Figure 5A ). The elevation in expression of Edn1 and Ednra and the reduced expression of Ednrb were evident as early as postnatal day 3 and persisted at days 7 and 21 and in adulthood. In agreement with mRNA levels, ET-1 peptide content in the lung tissue was also higher in Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice at postnatal day 7 ( Figure 5B) , and protein levels of ET B receptor were lower and those of ET A were higher ( Figure 5C and 5D) . Given the pronounced vasoconstrictive effects of the endothelin pathway, the changes observed in Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice could account for their propensity to develop pulmonary vascular remodeling and hypertension. 
Results are presented as meanϮSD in mm/s.
Discussion
By studying mice with loss-of-function mutations in genes required for LPA production and signaling, we have identified an unanticipated role for this mediator in protection from hypoxia-induced PH. We found that heterozygous inactivation of the LPA-producing enzyme autotaxin promotes the development of hypoxia-induced pulmonary arterial hypertension. Mice lacking LPA 1 and LPA 2 receptors were also more susceptible to hypoxia-induced pulmonary remodeling and spontaneously developed pulmonary arterial hypertension (characterized by elevated RVSP and increased pulmonary arteriolar muscularization and wall thickness) and RV hypertrophy with age. Our findings implicate both LPA 1 and LPA 2 as the main contributors to LPA's effect in the pulmonary vasculature. Because neither Lpar1 Ϫ/Ϫ nor Lpar2 Ϫ/Ϫ mice display the dramatic development of PH observed in Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice, we conclude that these receptors act redundantly to promote the relevant signaling pathways.
Our findings raise the possibility that LPA has distinct effects in the pulmonary and systemic vasculature. LPA has been widely reported to stimulate cultured SMC migration and proliferation, [13] [14] [15] direct LPA administration stimulates neointimal formation in rodent carotid arteries, 17 and systemic LPA administration elevates blood pressure acutely in rodents. 1 Based on its ability to promote migration and dedifferentiation of pulmonary vascular cells, LPA might be predicted to promote or exacerbate PH. LPA 1 and LPA 2 receptors regulate migratory responses in several cell types, including SMCs. 1, 34 It is possible that in the setting of attenuated LPA signaling, abnormal SMC migration results in a developmental abnormality of vessel formation that promotes PH. An alternative, but not exclusive, possibility is that LPA signaling plays a fundamental role in maintaining pulmonary vascular tone, and mice with inherited deficiencies in LPA signaling develop compensatory mechanisms to balance the loss of LPA, such as upregulation of endothelin signaling, that contribute to pathology. The ability of LPA to affect acutely systemic blood pressure in certain species was reported more than 30 years ago. However, to our knowledge, this is the first report to document the consequences of long-term deficiency of LPA signaling on vascular tone in an experimental model. Of interest is the observation that acute LPA administration alters systemic blood pressure but does not affect pulmonary resistance, whereas genetic deficiency in LPA signaling alters the pulmonary vasculature without affecting systemic blood pressure. It is possible that in the absence of LPA signaling, the endothelin pathway is upregulated to maintain systemic pressure at the expense of the pulmonary vasculature. LPA and endothelin share downstream signaling mediators, such as phospholipase C and D, and other work has identified unexpected consequences of genetic deletion of signaling pathways on other systems. Similar effects (for example, those mediated by alterations in coupling of receptors to G protein-coupled receptors) could account for upregulation of endothelin signaling in the absence of LPA receptors.
The development of PH may require several events, including a trigger (such as hypoxia), an imbalance in the ratio of vasodilators to vasoconstrictors, and a permissive genotype. 35 The spontaneous development of PH in the Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice may have been facilitated by permissive genetic modifiers on the BALB/c background. BALB/c mice are more prone than C3H and C57BL/6 mice to developing pulmonary vascular muscularization following smoke exposure. 36 Enhanced hypoxic pulmonary vasoconstriction in BALB/c mice compared with C57BL/6 mice has been observed. 37 The BALB/c background also modifies the phenotype of transforming growth factor-␤1-deficient mice, 38 and transforming growth factor-␤ signaling has been implicated in the development of PH. Differences of baseline cardiovascular phenotypes in mice on various genetic backgrounds are reported and may also explain the differences in peak flow velocity of normoxic Enpp2 and Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice. 39 The development of PH in the Enpp2 ϩ/Ϫ and the Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice was likely promoted by an imbalance in the ratio of vasodilators (nitric oxide and prostacyclins) to vasoconstrictors (ET-1 and thromboxane A 2 ). No difference in expression of enzymes responsible for production of NO (endothelial nitric oxide synthase) or termination of its signaling (phosphodiesterase 5) was observed, nor were there changes in urinary prostacyclin or thromboxane metabolites to account for the development of PH (data not shown). However, in both Enpp2 ϩ/Ϫ and the Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice, lower expression of Ednrb could promote pulmonary vasoconstriction. The elevation in ET-1 levels, which occurred in Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice by postnatal day 7, may also contribute to the propensity of these animals to develop PH.
Our findings suggest that there may be significant crosstalk between LPA and endothelin signaling systems that occurs directly or functionally. LPA and ET-1 stimulate many of the same vasoconstrictive and phenotypic changes in cultured SMCs. 40, 41 In rat aortic endothelial cells, LPA stimulates pre-proET-1 mRNA levels 42 and, in nonvascular SMCs, some of the effects of ET-1 may be related to production of LPA and signaling through LPA 1 . 43 Both LPA and endothelin have been shown to increase blood pressure acutely. 1, 44 Thus, in the settings of long-term deficiency of LPA signaling, such as the cases of Enpp2 ϩ/Ϫ and the Lpar1 Ϫ/Ϫ 2 Ϫ/Ϫ mice, compensatory changes in endothelin signaling pathways may occur that promote pathology. Precedent for this exists; mice that are deficient in cyclooxygenase 2 have an upregulation in ET A receptors and develop exacerbated hypoxia-induced PH. 45 Experiments are under way to elucidate the mechanism(s) of downregulation of Ednrb and hence enhanced endothelin signaling in the deficiency of LPA.
In conclusion, by studying mouse models with reduced LPA levels, as well as impaired LPA signaling, we identified important roles for LPA 1 and LPA 2 receptors in pulmonary development and in the maintenance of normal pulmonary vascular pressure. These results focus attention on the possibility that components of the LPA signaling system could be targets for pharmacological treatment of PH.
